Controlling Symptoms in Patients With MF Treated With Hypomethylating Agents
Srdan Verstovsek, MD, PhD, discusses how to control symptoms while using hypomethylating agents in patients with myelofibrosis.
Srdan Verstovsek, MD, PhD, professor in the Department of Leukemia and director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses how to control symptoms while using hypomethylating agents in patients with myelofibrosis (MF).
The hypomethylating agents are used solely to lower blast and control disease. In some cases, complete responses and partial responses with these agents have been reported, Verstovsek says, but the goal of these agents is to put the disease into a chronic phase with less than 10% blast so that the patient can receive transplant.
According to Verstovsek, the quality of life (QoL) on these agents is not great, while MF in general has many systemic symptoms that cannot be controlled by hypomethylating agents. However, to control the symptoms, the JAK inhibitor ruxolitinib (Jakafi) can be given in combination to help with QoL and the progressive nature of the disease.
Connecting Spleen Volume Reduction to Survival Outcomes in MF
April 21st 2024During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the correlation between spleen volume responses and survival outcomes for patients with myelofibrosis in the second article of a 2-part series.
Read More
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More
